deltatrials
Completed PHASE1 INTERVENTIONAL 2-arm NCT01729806

Ipilimumab and Rituximab in Treating Patients With Relapsed or Refractory B-cell Lymphoma

A Phase I Study of Ipilimumab in Combination With Rituximab in Patients With Relapsed/Refractory CD20+ B-Cell Lymphoma

Sponsor: National Cancer Institute (NCI)

Conditions CD20 Positive Recurrent B-Cell Non-Hodgkin Lymphoma Refractory B-Cell Non-Hodgkin Lymphoma
Interventions Ipilimumab Laboratory Biomarker Analysis Rituximab
Updated 9 times since 2017 Last updated: Apr 10, 2018 Started: Nov 19, 2012 Primary completion: Mar 30, 2018 Completion: Mar 30, 2018
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates CD20 Positive and Recurrent B-Cell Non-Hodgkin Lymphoma and is currently completed. National Cancer Institute (NCI) leads this study, which shows 9 recorded versions since 2012 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshotActive Not Recruiting~Feb 2017 – ~Jun 2017 · 4 months · monthly snapshotActive Not Recruiting~Jun 2017 – ~May 2018 · 11 months · monthly snapshotActive Not Recruiting~May 2018 – ~Jun 2018 · 31 days · monthly snapshotCompleted~Jun 2018 – ~Jan 2021 · 31 months · monthly snapshotCompleted~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshotCompleted~Sep 2025 – present · 10 months · monthly snapshotCompleted

Change History

9 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE1

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE1

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1

  4. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE1

  5. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE1

▶ Show 4 earlier versions

  1. May 2018 — Jun 2018 [monthly]

    Completed PHASE1

    Status: Active Not Recruiting → Completed

  2. Jun 2017 — May 2018 [monthly]

    Active Not Recruiting PHASE1

  3. Feb 2017 — Jun 2017 [monthly]

    Active Not Recruiting PHASE1

  4. Jan 2017 — Feb 2017 [monthly]

    Active Not Recruiting PHASE1

    First recorded

Nov 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • National Cancer Institute (NCI)
Data source: National Cancer Institute (NCI)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations